Research has indicated that PGK1 enhances glycolysis via CXCR4/ERK pathway activation, which is associated with sorafenib resistance in clear cell renal cell carcinoma (He et al., 2022). This evidence concerns the gene CXCR4 and clear cell renal carcinoma.